Rhenium Re 188 etidronate

Drug Profile

Rhenium Re 188 etidronate

Alternative Names: 188Re -HEDP

Latest Information Update: 08 Jan 2016

Price : $50

At a glance

  • Originator Jiangsu Lai Tai Medical Biotechnology
  • Developer Jiangsu Lai Tai Medical Biotechnology; Shanghai Institute of Applied Physics Chinese Academy of Sciences
  • Class Antineoplastics; Bisphosphonates; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cancer pain

Most Recent Events

  • 07 Jan 2016 Phase-II clinical trials in Cancer pain in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top